Monoclonal antibody successes in the clinic

被引：554

作者：

Reichert, JM ^{[1
]}

Rosensweig, CJ ^{[1
]}

Faden, LB ^{[1
]}

Dewitz, MC ^{[1
]}

机构：

[1] Tufts Univ, Ctr Study Drug Dev, Boston, MA 02111 USA

来源：

NATURE BIOTECHNOLOGY | 2005年 / 23卷 / 09期

关键词：

D O I：

10.1038/nbt0905-1073

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Most monoclonal antibodies in clinical trials are owned by small biotech companies. But with blockbuster-sized revenues and approval rates higher than those for small-molecule drugs, that all may be set to change. © 2005 Nature Publishing Group.

引用

页码：1073 / 1078

页数：6

共 15 条

[1] PRODUCTION OF FUNCTIONAL CHIMAERIC MOUSE HUMAN-ANTIBODY [J].

BOULIANNE, GL ;

HOZUMI, N ;

SHULMAN, MJ .

NATURE, 1984, 312 (5995) :643-646

[2]

Carson D A, 1986, Adv Immunol, V38, P275, DOI 10.1016/S0065-2776(08)60009-7

[3]

COLE SPC, 1984, MOL CELL BIOCHEM, V62, P109

[4]

FLEMING T, 2004, RED BOOK

[5] MONOCLONAL ANTIENDOTOXIN AGENT HA-1A (CENTOXIN) [J].

INGLIS, TJJ ;

LACEY, RW ;

KAY, E ;

HAWKEY, PM ;

BODENHAM, A ;

CALVERT, RT .

LANCET, 1993, 341 (8840) :303-303

[6] REPLACING THE COMPLEMENTARITY-DETERMINING REGIONS IN A HUMAN-ANTIBODY WITH THOSE FROM A MOUSE [J].

JONES, PT ;

DEAR, PH ;

FOOTE, J ;

NEUBERGER, MS ;

WINTER, G .

NATURE, 1986, 321 (6069) :522-525

[7] CONTINUOUS CULTURES OF FUSED CELLS SECRETING ANTIBODY OF PREDEFINED SPECIFICITY [J].

KOHLER, G ;

MILSTEIN, C .

NATURE, 1975, 256 (5517) :495-497

[8] Can the pharmaceutical industry reduce attrition rates? [J].

Kola, I ;

Landis, J .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) :711-715

[9]

Milstein C, 1999, BIOESSAYS, V21, P966, DOI 10.1002/(SICI)1521-1878(199911)21:11<966::AID-BIES9>3.3.CO

[10]

2-Q

← 1 2 →